Gilead and the Satcher Health Leadership Institute at Morehouse School of Medicine announced a new partnership to develop a real-time, public-facing and comprehensive health equity data platform to help address the impact of COVID-19 and other diseases on communities of color.
Throughout my education and during the first decade of my career as a clinical pharmacologist, I carried a huge burden. Around classmates and colleagues, I held a secret about who I really was – I was in the closet.
I hid this part of my identity because, like many LGBTQ+ individuals, I feared that my sexual orientation would limit or even jeopardize my career. When I began my scientific training, I didn’t have any openly gay role models to consult or rely upon. Without a well-defined path forward, it made me question what my future in science would be.
After receiving the green light from the FDA to move forward, Gilead is about to start trials of an inhaled version of remdesivir. We will screen healthy volunteers for Phase 1 trials this week and hope to begin studies in patients with COVID-19 in August. If the trials are successful, this could represent important progress. Remdesivir, our investigational antiviral medicine, is currently given to patients intravenously through daily infusions in the hospital.
By John Sayre, Senior Vice President of Development Operations at Gilead
When I was in college, I learned about the Spanish Flu in a class on the history of medicine. I found the pandemic so fascinating that I reached out to my grandmother Cordelia to ask her about it. She was about 80 by then but still remembered it vividly. She described driving through a neighborhood in Akron, Ohio at the age of 15 and seeing people throwing furniture out of an attic window. Everyone in the house had died, and they were burning everything inside to kill the germs.
Gilead views environmental stewardship as critical to help the company achieve its mission and last year announced a goal to reduce greenhouse gas emissions at least 25% by 2025, against a 2016 baseline.
As the number of confirmed COVID-19 cases increased in Asia and began to spread to other regions around the world, a team of employees at Gilead’s manufacturing site in La Verne, California met in the early morning of Monday, Feb. 3.
The topic of the meeting: How quickly could the site begin to formulate, fill, package and ship Gilead’s investigational COVID-19 treatment, remdesivir?
Nearly a year ago, President Trump announced an aspirational goal in his State of the Union address: to reduce the number of new HIV infections in the U.S. by 75% within five years, and by at least 90% within 10 years. This goal is certainly ambitious – but it is not unreachable.